325 related articles for article (PubMed ID: 35986858)
1. New Advances in Supportive Care: Chemoprotective Agents as Novel Opportunities in Geriatric Oncology.
Balducci L; Falandry C; List A
Curr Oncol Rep; 2022 Dec; 24(12):1695-1703. PubMed ID: 35986858
[TBL] [Abstract][Full Text] [Related]
2. A Proactive Approach to Prevent Hematopoietic Exhaustion During Cancer Chemotherapy in Older Patients: Temporary Cell-Cycle Arrest.
Balducci L; Falandry C; List A
Drugs Aging; 2023 Mar; 40(3):263-272. PubMed ID: 36715830
[TBL] [Abstract][Full Text] [Related]
3. Cell cycle arrest: A breakthrough in the supportive care of older cancer patients.
Falandry C; List A; Balducci L
J Am Geriatr Soc; 2023 Jul; 71(7):2297-2307. PubMed ID: 37036091
[TBL] [Abstract][Full Text] [Related]
4. Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials.
Ferrarotto R; Anderson I; Medgyasszay B; García-Campelo MR; Edenfield W; Feinstein TM; Johnson JM; Kalmadi S; Lammers PE; Sanchez-Hernandez A; Pritchett Y; Morris SR; Malik RK; Csőszi T
Cancer Med; 2021 Sep; 10(17):5748-5756. PubMed ID: 34405547
[TBL] [Abstract][Full Text] [Related]
5. Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies.
Weiss J; Goldschmidt J; Andric Z; Dragnev KH; Gwaltney C; Skaltsa K; Pritchett Y; Antal JM; Morris SR; Daniel D
Clin Lung Cancer; 2021 Sep; 22(5):449-460. PubMed ID: 33895103
[TBL] [Abstract][Full Text] [Related]
6. Trilaciclib and the economic value of multilineage myeloprotection from chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer treated with first-line chemotherapy.
Abraham I; Onyekwere U; Deniz B; Moran D; Chioda M; MacDonald K; Huang H
J Med Econ; 2021 Nov; 24(sup1):71-83. PubMed ID: 34873975
[TBL] [Abstract][Full Text] [Related]
7. Budget impact analysis of trilaciclib for decreasing the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer in the United States.
Abraham I; Goyal A; Deniz B; Moran D; Chioda M; MacDonald KM; Huang H
J Manag Care Spec Pharm; 2022 Apr; 28(4):435-448. PubMed ID: 35100006
[No Abstract] [Full Text] [Related]
8. Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study.
Hart LL; Ferrarotto R; Andric ZG; Beck JT; Subramanian J; Radosavljevic DZ; Zaric B; Hanna WT; Aljumaily R; Owonikoko TK; Verhoeven D; Xiao J; Morris SR; Antal JM; Hussein MA
Adv Ther; 2021 Jan; 38(1):350-365. PubMed ID: 33123968
[TBL] [Abstract][Full Text] [Related]
9. The impact of myelosuppression on quality of life of patients treated with chemotherapy.
Crawford J; Herndon D; Gmitter K; Weiss J
Future Oncol; 2024 Apr; ():. PubMed ID: 38587388
[TBL] [Abstract][Full Text] [Related]
10. Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung cancer.
Dómine Gómez M; Csőszi T; Jaal J; Kudaba I; Nikolov K; Radosavljevic D; Xiao J; Horton JK; Malik RK; Subramanian J
Int J Cancer; 2021 Oct; 149(7):1463-1472. PubMed ID: 34109630
[TBL] [Abstract][Full Text] [Related]
11. Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial.
Weiss JM; Csoszi T; Maglakelidze M; Hoyer RJ; Beck JT; Domine Gomez M; Lowczak A; Aljumaily R; Rocha Lima CM; Boccia RV; Hanna W; Nikolinakos P; Chiu VK; Owonikoko TK; Schuster SR; Hussein MA; Richards DA; Sawrycki P; Bulat I; Hamm JT; Hart LL; Adler S; Antal JM; Lai AY; Sorrentino JA; Yang Z; Malik RK; Morris SR; Roberts PJ; Dragnev KH;
Ann Oncol; 2019 Oct; 30(10):1613-1621. PubMed ID: 31504118
[TBL] [Abstract][Full Text] [Related]
12. Myeloprotection with trilaciclib in Chinese patients with extensive-stage small cell lung cancer receiving chemotherapy: Results from a randomized, double-blind, placebo-controlled phase III study (TRACES).
Cheng Y; Wu L; Huang D; Wang Q; Fan Y; Zhang X; Fan H; Yao W; Liu B; Yu G; Pan Y; Xu F; He Z; Dong X; Ma R; Min X; Ge X; Chen H; Liu Q; Hu Y; Liu Y; Yang C; Yang Y; Li X; Zhou L
Lung Cancer; 2024 Feb; 188():107455. PubMed ID: 38224653
[TBL] [Abstract][Full Text] [Related]
13. Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies.
Hussein M; Maglakelidze M; Richards DA; Sabatini M; Gersten TA; Lerro K; Sinielnikov I; Spira A; Pritchett Y; Antal JM; Malik R; Beck JT
Cancer Manag Res; 2021; 13():6207-6218. PubMed ID: 34408488
[TBL] [Abstract][Full Text] [Related]
14. Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial.
Tan AR; Wright GS; Thummala AR; Danso MA; Popovic L; Pluard TJ; Han HS; Vojnović Ž; Vasev N; Ma L; Richards DA; Wilks ST; Milenković D; Yang Z; Antal JM; Morris SR; O'Shaughnessy J
Lancet Oncol; 2019 Nov; 20(11):1587-1601. PubMed ID: 31575503
[TBL] [Abstract][Full Text] [Related]
15. A time for hope: promising advances in the management of anemia, neutropenia, thrombocytopenia, and mucositis.
Kurtin SE
J Support Oncol; 2007 Apr; 5(4 Suppl 2):85-8. PubMed ID: 17550057
[TBL] [Abstract][Full Text] [Related]
16. Improving Outcomes of Chemotherapy: Established and Novel Options for Myeloprotection in the COVID-19 Era.
Lyman GH; Kuderer NM; Aapro M
Front Oncol; 2021; 11():697908. PubMed ID: 34307165
[TBL] [Abstract][Full Text] [Related]
17. Real-World Outcomes of Trilaciclib Among Patients with Extensive-Stage Small Cell Lung Cancer Receiving Chemotherapy.
Goldschmidt J; Hart L; Scott J; Boykin K; Bailey R; Heritage T; Lopez-Gonzalez L; Zhou ZY; Edwards ML; Monnette A; Ogbonnaya A; Deyoung K; Venkatasetty D; Shi P; Aton L; Huang H; Conkling PR; Gordan L
Adv Ther; 2023 Oct; 40(10):4189-4215. PubMed ID: 37490258
[TBL] [Abstract][Full Text] [Related]
18. Bone marrow-sparing and prevention of alopecia by AS101 in non-small-cell lung cancer patients treated with carboplatin and etoposide.
Sredni B; Albeck M; Tichler T; Shani A; Shapira J; Bruderman I; Catane R; Kaufman B; Kalechman Y
J Clin Oncol; 1995 Sep; 13(9):2342-53. PubMed ID: 7666093
[TBL] [Abstract][Full Text] [Related]
19. Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer.
Li C; Hart L; Owonikoko TK; Aljumaily R; Rocha Lima CM; Conkling PR; Webb RT; Jotte RM; Schuster S; Edenfield WJ; Smith DA; Sale M; Roberts PJ; Malik RK; Sorrentino JA
Cancer Chemother Pharmacol; 2021 May; 87(5):689-700. PubMed ID: 33595690
[TBL] [Abstract][Full Text] [Related]
20. CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy.
Lai AY; Sorrentino JA; Dragnev KH; Weiss JM; Owonikoko TK; Rytlewski JA; Hood J; Yang Z; Malik RK; Strum JC; Roberts PJ
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33004541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
